Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder

Dyslipidemia and Mental Illness

“…An earlier study with rosuvastatin proved effective in managing dyslipidemia in schizophrenic patients on antipsychotics. This study showed improvement in lipid profiles but not benefits in terms of high-density lipoprotein, waist measurement, BMI or glucose homeostasis (De Hert et al, 2006). This last study supports the view that statins can be safely used in the short term to control abnormal lipids levels.…”

Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms

“…amantadine), serotonin reuptake inhibitors, sympathomimetics, metformin and orlistat (which inhibits fat absorption from the gastrointestinal tract) (Gracious and Meyer, 2005). For the treatment of dyslipidemia, the use of statins is effective in antipsychotic-treated schizophrenic patients, with a significant decrease in triglycerides and in total and LDL cholesterol (Andrade, 2013;De Hert et al, 2006a;Hanssens et al, 2007). Statins use should therefore be considered for the primary prevention of cardiovascular side-effects associated with antipsychotic therapy (Andrade, 2013).…”

Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach

“…There is concern that statins may have a compounding effect with antipsychotic medication in increasing the risk of diabetes as statins have been found to increase the risk for insulin resistance. Thus far, studies investigating the use of a statin in patients on antipsychotic medications over a short period did not find an increase in fasting glucose or HbA1c levels 83,84. There does not appear to be evidence against using statins for patients on antipsychotics as determined by general guidelines for hyperlipidemia.…”